Humanized Anti-CD22 Recombinant Antibody (clone Pinatuzumab) (CAT#: TAB-899)

Figure 1 Incidence of >10% of all treatment-emergent AEs in patients receiving single-agent pinatuzumab vedotin (2.4 mg/kg): iNHL versus DLBCL.

Most AEs reported in the 39 NHL patients treated at the RP2D (2.4 mg/kg) were grade 1–2 in severity. Twenty-seven (69%) patients reported grade 3–4 adverse events; the most common in ≥2 patients included neutropenia, fatigue, peripheral sensory neuropathy, hyperglycemia, and anemia. Grade 3 febrile neutropenia was reported in one patient. Serious AEs were reported in 13 (33%) NHL patients. Pyrexia was reported in 3 patients and dyspnea in 2 patients; otherwise, no single serious AE was reported in ≥2 patients. Thirteen (33%) patients discontinued pinatuzumab vedotin treatment due to an AE.

Advani, R. H., Lebovic, D., Chen, A., Brunvand, M., Goy, A., Chang, J. E., ... & Agarwal, P. (2017). Phase I study of the anti-CD22 antibody–drug conjugate pinatuzumab vedotin with/without rituximab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clinical Cancer Research, 23(5), 1167-1176.

Figure 2 Tumor reductions were mostly observed at pinatuzumab vedotin doses ≥1.8 mg/kg.

Observed antitumor responses in DLBCL patients (A) and iNHL patients (B). Dashed lines indicate 50% increases and 50% decreases in SPD from baseline. R, refractory; SPD, sum of the product of the diameters.

Advani, R. H., Lebovic, D., Chen, A., Brunvand, M., Goy, A., Chang, J. E., ... & Agarwal, P. (2017). Phase I study of the anti-CD22 antibody–drug conjugate pinatuzumab vedotin with/without rituximab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clinical Cancer Research, 23(5), 1167-1176.

Figure 1 Recombinant Human Anti-CD22 Antibody (TAB-899) in WB

Western blot analysis of TAB-899 was performed with CD22 Protein, Human, Recombinant (His Tag).
TAB-899 incubation concentration: 2ng/μL.
The secondary antibody: HRP-Anti-Human IgG (H+L)
Lane 1: Reducing antigen (0.1μg)
Lane 2: Reducing antigen (0.3μg)
Lane 3: Reducing antigen (0.6μg)

Figure 2 Recombinant Human Anti-CD22 Antibody (TAB-899) in DB

Dot blot analysis of TAB-899 was performed with CD22 Protein, Human, Recombinant (His Tag).
TAB-899 incubation concentration: 2ng/μL.
NC: Negative control PC: Positive control

Figure 3 Recombinant Human Anti-CD22 Antibody (TAB-899) in Flow Cytometry

Flow cytometry analysis of Daudi cells with anti-CD22 antibody (Cat#TAB-899, Blue line) or isotype control antibody (Yellow line). A Goat Anti-human IgG (FITC) was used as the secondary antibody.